Regeneron Pharmaceuticals (REGN) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

REGN ranks #292 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1347 institutions disclose a position in REGN, but none treat it as a major bet — even Dodge & Cox, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Invesco Ltd. has added to its REGN position for two straight quarters, increasing it by $1.2B to reach $2.5B today.

Fidelity has trimmed its REGN position for two straight quarters, cutting it by $1.3B while still holding $518.8M.

REGN is up 3.1% today, and institutions have been net buyers of $31.7B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

REGN posted net income of $4.3B over the trailing twelve months, and currently trades at a P/E of 20.7.

• Profitable — net income of $4.3B over the trailing twelve months
• Revenue grew 9.3% year over year
• Net income declined year over year, from $4.5B to $4.3B
• Generated $5.0B in positive operating cash flow
• Current ratio of 4.13x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.30x equity — within a conventional range